Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.
Request informationBack
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
Contact Information
When you want to bring clarity and personalization to your prostate cancer treatment discussions, go beyond risk stratification at biopsy with Prolaris testing.
Patients want to be confident that their doctors treatment recommendation is THEIR best option. Prolaris delivers a personalized risk assessment of a patient’s prostate cancer by combining clinically proven information with traditional diagnostic tools like PSA and Gleason.
of biopsy and surgical Gleason scores do not match.1
of the time, expert-trained GU pathologists disagree about biopsy Gleason scores.2
Improving the patient experience through genomics
When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. Prolaris is the only test studied in untreated patients and can identify the MOST patients for active surveillance across all biomarkers.4
The Prolaris test combines genomic (CCP) and clin-path features. CCP is the gold standard for measuring cancer aggressiveness.
The Prolaris test is validated in 10,000 patients across all risk groups.3
Prolaris is two times more prognostic than PSA/Gleason alone8
Prolaris has an independent CCP score that determines cancer aggressiveness and is combined with more traditional clinical pathological features like PSA and Gleason to create the most prognostic test on the market.
Prolaris can identify which men are safe for active surveillance and those who are not. With two clinically validated thresholds, Prolaris can also identify which patients should consider actively treating their cancer with one form of treatment, like surgery or radiation, and which patients will benefit from multiple forms of treatment
Identify active surveillance (AS) patients at time of biopsy
Because the Prolaris® test was developed and validated on untreated men,4 AS conversations with the untreated patient in front of you are more relevant and informed.
The Prolaris test outperforms all other biomarkers in identifying the right patients for active surveillance in both low and intermediate risk populations4
In the Prolaris validation study, NO patient below the AS threshold died of prostate cancer4
The Prolaris biomarker best aligns with patients studied in ProtecT, the largest randomized trial of AS or treatment in screen-detected localized prostate cancer5
Identify the patients who need definitive treatment and at what intensity
The Prolaris® test shows that those patients who fall below the multi-modal threshold do not benefit from intensifying treatment6
Establishing the multi-modal threshold
The Prolaris test threshold was developed on approximately 1,500 intermediate and high-risk patients from two separate cohorts
Validating patients prior to a multi-modal treatment
Patients were separated by those who received single-modal therapy versus those with multiple modes of treatment
Guide the androgen deprivation therapy (ADT) conversation
Multiple groups with ADT variations evaluated for metastasis
The Multi-modal threshold was developed and double-validated across all outcomes to predict the risk of metastasis and determine which patients can safely forego ADT6,7
At or below the multi-modal threshold(8.8% metastasis risk)
The Prolaris® test gives your patients personalized, shareable guidance and a simple “number-needed-to-treat” value
Is ADT right for this patient?
View Prolaris report
2x the predictive power of PSA and Gleason combined8
Outperforms all other biomarkers in active surveillance9
Only test developed and validated on untreated men4
Most comprehensive: combines genomic, PSA and Gleason scores8
Goes beyond risk stratification to determine which patients need treatment and the appropriate level of intensity
Personalizes ADT decisions with ARR for every patient
For you and the patient in front of you, when it comes to finding the best tool to bring clarity, utility and personalization to your prostate cancer treatment discussions, the conversation just got easier.
The complete suite of tests for a full prostate cancer workup.
Myriad UroSuite gives healthcare providers the ability to directly order a complete suite of tests – including biomarker, germline, and somatic – for clear, comprehensive insights to guide prostate cancer treatment.
Every Prolaris test provides actionable results to inform more confident prostate cancer treatment decisions.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.
References: